🇺🇸 FDA
Pipeline program

APVO210

8001

Phase 1 mab terminated

Quick answer

APVO210 for Psoriasis is a Phase 1 program (mab) at Aptevo Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aptevo Therapeutics
Indication
Psoriasis
Phase
Phase 1
Modality
mab
Status
terminated

Clinical trials